株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

難治性急性骨髄性白血病:パイプライン分析

Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 305180
出版日 ページ情報 英文 489 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
難治性急性骨髄性白血病:パイプライン分析 Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2016
出版日: 2016年05月25日 ページ情報: 英文 489 Pages
概要

難治性急性骨髄性白血病の症状には、チアノーゼ、歯茎の腫れ、肛門周囲の痛み、食欲不振、体重の減少、骨や関節の痛み/違和感などが症状として現れます。この疾患を罹患する要素として、老齢化、過去に血液関係の癌やその他疾患を罹患したことがあることなどが挙げられます。

当レポートでは、世界各国での難治性急性骨髄性白血病治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

難治性急性骨髄性白血病の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

難治性急性骨髄性白血病:企業で開発中の治療薬

難治性急性骨髄性白血病:大学/研究機関で開発中の治療薬

難治性急性骨髄性白血病:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

難治性急性骨髄性白血病:企業で開発中の製品

難治性急性骨髄性白血病:大学/研究機関で開発中の製品

難治性急性骨髄性白血病の治療薬開発に従事している企業

  • 4SC AG
  • AbbVie Inc.
  • Actinium Pharmaceuticals, Inc.
  • Aeglea BioTherapeutics, Inc.
  • Agios Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arog Pharmaceuticals, Inc.
  • Array BioPharma Inc.
  • アステラス製薬
  • AVEO Pharmaceuticals, Inc.
  • Bellicum Pharmaceuticals, Inc.
  • BioLineRx, Ltd.
  • BioSight Ltd.
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Calithera Biosciences, Inc.
  • Celgene Corporation
  • Cornerstone Pharmaceuticals, Inc.
  • CTI BioPharma Corp.
  • 第一三共
  • エーザイ
  • EpiZyme, Inc.
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • FORMA Therapeutics, Inc.
  • 富士フイルム
  • GlaxoSmithKline Plc
  • GlycoMimetics, Inc.
  • Igenica Biotherapeutics, Inc.
  • Incyte Corporation
  • Jiangsu Hansoh Pharmaceutical Co., Ltd.
  • Johnson & Johnson
  • JW Pharmaceutical Corporation
  • Karyopharm Therapeutics, Inc.
  • 協和発酵キリン
  • Les Laboratoires Servier SAS
  • MacroGenics, Inc.
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • NantKwest, Inc.
  • Novartis AG
  • Oxford BioTherapeutics Ltd
  • Pfizer Inc.
  • Pharma Mar, S.A.
  • Plexxikon Inc.
  • Polaris Pharmaceuticals, Inc.
  • Seattle Genetics, Inc.
  • Sigma-Tau S.p.A. 82
  • Sunesis Pharmaceuticals, Inc.
  • TaiGen Biotechnology Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Threshold Pharmaceuticals, Inc.
  • Tolero Pharmaceuticals, Inc.
  • Tragara Pharmaceuticals, Inc.
  • Verastem, Inc.

難治性急性骨髄性白血病:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

難治性急性骨髄性白血病:最近のパイプライン動向

難治性急性骨髄性白血病:休止中のプロジェクト

難治性急性骨髄性白血病:開発が中止された製品

難治性急性骨髄性白血病:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8002IDB

Summary

Global Markets Direct's, 'Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2016', provides an overview of the Refractory Acute Myeloid Leukemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Refractory Acute Myeloid Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Refractory Acute Myeloid Leukemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Refractory Acute Myeloid Leukemia
  • The report reviews pipeline therapeutics for Refractory Acute Myeloid Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Refractory Acute Myeloid Leukemia therapeutics and enlists all their major and minor projects
  • The report assesses Refractory Acute Myeloid Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Refractory Acute Myeloid Leukemia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Refractory Acute Myeloid Leukemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Refractory Acute Myeloid Leukemia Overview
  • Therapeutics Development
  • Refractory Acute Myeloid Leukemia - Therapeutics under Development by Companies
  • Refractory Acute Myeloid Leukemia - Therapeutics under Investigation by Universities/Institutes
  • Refractory Acute Myeloid Leukemia - Pipeline Products Glance
  • Refractory Acute Myeloid Leukemia - Products under Development by Companies
  • Refractory Acute Myeloid Leukemia - Products under Investigation by Universities/Institutes
  • Refractory Acute Myeloid Leukemia - Companies Involved in Therapeutics Development
  • Refractory Acute Myeloid Leukemia - Therapeutics Assessment
  • Drug Profiles
  • Refractory Acute Myeloid Leukemia - Recent Pipeline Updates
  • Refractory Acute Myeloid Leukemia - Dormant Projects
  • Refractory Acute Myeloid Leukemia - Discontinued Products
  • Refractory Acute Myeloid Leukemia - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Refractory Acute Myeloid Leukemia, H1 2016
  • Number of Products under Development for Refractory Acute Myeloid Leukemia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by 4SC AG, H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by AbbVie Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Aeglea BioTherapeutics, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Agios Pharmaceuticals, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Amgen Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Arog Pharmaceuticals, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Array BioPharma Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Astellas Pharma Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by BioLineRx, Ltd., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by BioSight Ltd., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Boston Biomedical, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Calithera Biosciences, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Celgene Corporation, H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by CTI BioPharma Corp., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Eisai Co., Ltd., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by EpiZyme, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Exelixis, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by FORMA Therapeutics, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Fujifilm Corporation, H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by GlycoMimetics, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Igenica Biotherapeutics, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Incyte Corporation, H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Johnson & Johnson, H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by JW Pharmaceutical Corporation, H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Les Laboratoires Servier SAS, H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by MacroGenics, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Merck & Co., Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by NantKwest, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Novartis AG, H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Oxford BioTherapeutics Ltd, H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Pfizer Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Pharma Mar, S.A., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Plexxikon Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Seattle Genetics, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Sigma-Tau S.p.A., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Sunesis Pharmaceuticals, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Tolero Pharmaceuticals, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Tragara Pharmaceuticals, Inc., H1 2016
  • Refractory Acute Myeloid Leukemia - Pipeline by Verastem, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Refractory Acute Myeloid Leukemia Therapeutics - Recent Pipeline Updates, H1 2016
  • Refractory Acute Myeloid Leukemia - Dormant Projects, H1 2016
  • Refractory Acute Myeloid Leukemia - Dormant Projects (Contd..1), H1 2016
  • Refractory Acute Myeloid Leukemia - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Refractory Acute Myeloid Leukemia, H1 2016
  • Number of Products under Development for Refractory Acute Myeloid Leukemia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top